Mounjaro Surpasses Keytruda as Top-Selling Medicine Worldwide
Mounjaro Takes the Lead in Pharmaceutical Sales
In a significant development for the global pharmaceutical sector, Mounjaro, a treatment for diabetes and obesity created by Eli Lilly, has officially surpassed Keytruda to become the highest-selling medication globally. This shift underscores the surging demand for therapies targeting obesity and diabetes, particularly the innovative GLP-1 and dual-action metabolic drugs that are rapidly changing healthcare landscapes around the world. Recent quarterly sales figures indicate that Mounjaro generated approximately $8.7 billion in revenue during the first quarter of 2026, outpacing Keytruda’s $7.9 billion in sales for the same timeframe. Keytruda, produced by Merck & Co., has been a dominant force in the pharmaceutical market since 2023, being an immunotherapy drug used for treating nearly 22 different types of cancer, and remains a crucial cancer treatment. However, the swift ascent of anti-obesity and diabetes medications is now altering the pharmaceutical environment.
Reasons Behind Mounjaro's Rising Popularity
Why is Mounjaro seeing a massive demand?
Mounjaro features tirzepatide, a cutting-edge molecule that targets both GLP-1 and GIP receptors in the body. It is prescribed for managing type 2 diabetes and aiding weight loss, as it effectively regulates blood sugar levels, appetite, and metabolism. Health professionals attribute the drug’s increasing popularity to the escalating global challenges posed by obesity and diabetes. The World Health Organization reported that in 2022, approximately 890 million adults worldwide were living with obesity, while nearly 590 million adults had diabetes. The heightened emphasis on metabolic health, weight management, and preventive healthcare has propelled the demand for GLP-1 therapies to unprecedented levels globally.
India: A Key Market for Mounjaro
India emerges as a major growth market
India has rapidly become one of the leading markets for Mounjaro. Data from Pharmarack indicates that the medication became the highest-selling drug by value in India as of April 2026 and has consistently ranked among the top therapies since its introduction in March 2025. Over the past year, Mounjaro reportedly achieved nearly Rs 1,009 crore in domestic sales, reflecting robust demand from Indian patients seeking advanced treatments for diabetes and obesity. Medical professionals note that Indian consumers are increasingly willing to invest in premium chronic therapies that promise substantial lifestyle and long-term health benefits.
Intensifying Competition in Weight-Loss Medications
Competition in the weight-loss drug market
The global race for obesity medications has intensified with the emergence of semaglutide-based treatments like Wegovy and Ozempic from Novo Nordisk. India has also seen an influx of more affordable semaglutide alternatives following patent expirations earlier this year. Despite the growing competition, Mounjaro continues to lead in sales by value, indicating a strong preference among healthcare providers and patients for these newer-generation metabolic therapies.
Transforming Global Healthcare with Obesity Drugs
Obesity drugs are reshaping global healthcare
Analysts in the global healthcare sector now regard GLP-1 and dual-action metabolic therapies as some of the most significant pharmaceutical advancements of the decade. Medications like Mounjaro and Zepbound have swiftly transformed the landscape of obesity and diabetes treatment, generating extraordinary demand worldwide. Industry estimates suggest that the combined global sales of these two drugs exceeded $36 billion in 2025, reportedly surpassing the annual revenue of Keytruda, which has long been viewed as one of the highest-selling medications globally. The remarkable growth of these therapies indicates a broader shift in contemporary healthcare. For many years, obesity was primarily seen as a lifestyle issue; however, medical experts are increasingly recognizing it as a chronic metabolic disease associated with severe complications, including type 2 diabetes, heart disease, fatty liver disease, sleep apnea, and certain cancers. GLP-1 and dual-action medications function by regulating appetite, enhancing insulin response, slowing gastric emptying, and facilitating significant long-term weight loss. Their effectiveness has prompted healthcare providers and policymakers to reconsider obesity management beyond traditional diet and exercise approaches. Experts believe these medications could fundamentally alter preventive healthcare by reducing obesity-related illnesses, lowering long-term healthcare expenses, and enhancing the quality of life for millions around the globe.